Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Potassium Binders: Safety Comes First!
Javed Butler, MD, MPH, MBA
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
The Critical Interplay: CKD, HF, and HyperkaleAmia
Potassium Binders in Practice: Clinical Trial Evidence
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Bernhard Hellmich, MD
Achieving Success in IgAN & FSGS
Siân Griffin, MD, PhD
Jürgen Floege, MD
Loreto Gesualdo, MD, FERA
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Jonathan Barratt, MD, PhD
Donald E. Kohan, MD, PhD
Separating Fact from Fiction: The Realities of CKD-aP
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Antoine Lanot, MD, PhD
Case-Based Management of AAV
Annette Bruchfeld, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.